OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $5.40 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.51, a 111.11% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.61, a 32.21% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.85, a 55.87% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.47, a 38.56% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $6.45, a 57.70% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $4.09, a 5.41% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $3.88, a 26.80% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $3.06, a 39.29% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.40 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $5.51 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $6.45 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $2.83 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $2.63 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $2.61 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $4.09 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $3.64 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.86 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $3.85 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $3.88 10-K · filed 2024-03-11 | |||
| 2023-09-30 | $3.85 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $3.77 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.47 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $3.06 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $2.71 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $3.00 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $4.02 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $5.04 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $3.38 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $2.49 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $4.41 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |